Q32 Bio Inc. (QTTB)
| Market Cap | 230.42M+158.9% |
| Revenue (ttm) | 53.74M |
| Net Income | 33.79M |
| EPS | 3.15 |
| Shares Out | 29.77M |
| PE Ratio | 2.46 |
| Forward PE | -7.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,033 |
| Open | 7.94 |
| Previous Close | 7.99 |
| Day's Range | 7.62 - 7.94 |
| 52-Week Range | 1.91 - 23.57 |
| Beta | -0.11 |
| Analysts | Strong Buy |
| Price Target | 39.60(+411.63%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$QTTB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in QTTB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by QTTB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
QTTB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New QTTB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to QTTB from public contracts
Source: USAspending.gov
QTTB Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from QTTB’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score